Development of a novel class of pharmacodynamic hybrids/no donors that targets cox-2 selectively and a machine-assisted flow procedure for the synthesis of meclinertant, a neurotensin receptor probe

The work described below is divided into two parts. In the first chapter, the development of a novel class of pharmacodynamic hybrids is discussed. These compounds are endowed with analgesic/anti-inflammatory properties along with their ability to release nitric oxide which makes them an important contribution to the development of effective COX-Inhibiting Nitric Oxide Donors. In the second chapter, the synthesis of an important neurotensin receptor antagonist (SR 48692, Meclinertant) is described. The synthesis of Meclinertant is achieved with the use of machine-assisted flow protocols through a robust, reliable and scalable route.